Zejula

Zejula (niraparib) is an oral prescription medication used in cancer care. It belongs to the PARP inhibitor class, supporting targeted therapy approaches. This page provides neutral, factual details about its use and handling. Always consult a healthcare provider for personalized guidance.

Zejula is primarily used in the treatment of certain types of ovarian cancer, including maintenance therapy after response to platinum-based chemotherapy. It is also utilized in select cases of fallopian tube or peritoneal cancer. Patients and caregivers often ask, 'what is niraparib used for' to understand its role in cancer management. Its mechanism supports DNA repair inhibition in cancer cells.

As with many medications, niraparib may cause effects such as fatigue, nausea, or digestive changes. Some individuals report dizziness or headaches during treatment. These effects vary by person and are typically monitored by a healthcare team. Regular check-ins help manage any concerns that arise.

Niraparib should be handled with care, especially by those with known allergies to its components. Blood counts are often monitored due to potential effects on bone marrow. Patients are advised to report any unusual symptoms promptly. Keep this medication stored securely, away from children and pets.

Niraparib may interact with other medications, including certain antidepressants, antifungals, or blood thinners. Strong CYP3A4 inhibitors or inducers can alter its levels in the body. Alcohol use may intensify side effects like drowsiness. Always disclose all medications and supplements to your healthcare provider before starting niraparib.